22:34 , Jul 17, 2019 |  BC Extra  |  Financial News

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round. Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and...
23:27 , Jul 15, 2019 |  BC Extra  |  Financial News

AI play Recursion raises $121M to expand into new drug discovery

Recursion’s $121 million series C round will allow the company to expand its artificial intelligence-based drug repurposing platform for rare diseases and develop capabilities for new drug discovery while pushing its pair of lead programs...
01:30 , Jul 13, 2019 |  BioCentury  |  Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
21:34 , May 28, 2019 |  BC Extra  |  Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
19:41 , May 16, 2019 |  BC Extra  |  Company News

Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver diseases and celiac disease. Parvus Therapeutics...
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
22:59 , Nov 30, 2018 |  BioCentury  |  Emerging Company Profile

Afyx: Mucosal drug delivery

Afyx Therapeutics is developing bioadhesive patches for mucosal drug delivery to address diseases that are inadequately treated by topical agents. Diseases affecting topically accessible mucosal sites, such as the buccal mucosa, are difficult to treat...
20:06 , Oct 5, 2018 |  BC Week In Review  |  Financial News

ArunA raises $5.3M

ArunA Biomedical Inc. (Athens, Ga.) said it raised $5.3 million from existing undisclosed angel investors. ArunA’s neural exosome platform allows drugs and drug combinations to cross the blood brain barrier. The company announced in January...
21:44 , Oct 4, 2018 |  BC Innovations  |  Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...
18:16 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda...